Report overview
The global CAR T-Cell-Based Drug market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
CD19-targeted Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of CAR T-Cell-Based Drug include Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics, Autolus Therapeutics and Sorrento Therapeutics, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
This report aims to provide a comprehensive presentation of the global market for CAR T-Cell-Based Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR T-Cell-Based Drug. This report contains market size and forecasts of CAR T-Cell-Based Drug in global, including the following market information:
Global CAR T-Cell-Based Drug Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
We surveyed the CAR T-Cell-Based Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global CAR T-Cell-Based Drug Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global CAR T-Cell-Based Drug Market Segment Percentages, by Type, 2023 (%)
CD19-targeted
BCMA-targeted
Global CAR T-Cell-Based Drug Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global CAR T-Cell-Based Drug Market Segment Percentages, by Application, 2023 (%)
Lymphoma
Multiple Myeloma
Global CAR T-Cell-Based Drug Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global CAR T-Cell-Based Drug Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies CAR T-Cell-Based Drug revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies CAR T-Cell-Based Drug revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
Outline of Major Chapters:
Chapter 1: Introduces the definition of CAR T-Cell-Based Drug, market overview.
Chapter 2: Global CAR T-Cell-Based Drug market size in revenue.
Chapter 3: Detailed analysis of CAR T-Cell-Based Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of CAR T-Cell-Based Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
